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SUMMARY Pegylated interferon α (PEG-IFN-α) is a formulation of 
recombinant human interferon conjugated with polyethylene-glycol. This 
preparation has a long half-life (compared with conventional IFN), which 
allows for once-weekly injection. Elimination half-life of PEG-IFN-α 2b is 
22-60 hours (average, 35-40 hours). We report the development of a local 
necrotizing reaction complicating subcutaneous injection of PEG-IFN in a 
patient with hepatitis C. This case enhances the need of careful training in 
drug reconstitution and self injection, with as much variation as possible 
of the injection site.
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IntRodUCtIon
 Type 1 interferons (IFN) are a group of proteins 
with antiviral, antiproliferative and immunoregula-
tory actions. IFN-α is currently employed in the 
treatment of viral hepatitis, Kaposi’s sarcoma, ma-
lignant melanoma, renal cell carcinoma, hairy cell 
leukemia and chronic myelogenous leukemia. A 
greater efficacy in the treatment of chronic hepati-
tis C has been recently achieved with once-weekly 
dosing of PEG-IFN-α in combination with ribavirin, 
which is now the standard therapeutic protocol for 
hepatitis C (1). PEG-IFN-α has a molecular weight 
of approximately 12 kD, is reabsorbed more slowly 
and therefore remains in the circulation longer than 
conventional IFN-α. This therapeutic combination 
may be responsible for systemic and cutaneous 
side effects. Local reactions at the sites of IFN in-
jection may be the cause of significant concern. 
A common side effect at injection site is localized 
inflammatory skin lesion, which may occasionally 
progress to skin necrosis with ulceration (2-6).
CASe RepoRt
 A 48-year-old Caucasian male was receiving 
once-weekly subcutaneous injection of PEG-IFN-
α 2b (100 µg) and oral ribavirin (1000 mg per day) 
for chronic active hepatitis C (HCV-RNA genotype 
1b, Ishak stage=2). After 6 months of therapy, the 
patient noted the appearance of an indurated and 
erythematous plaque on the right shoulder, three 
cm below the usual area of injection. The patient 
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continued to inject himself at the same site, al-
ternating with the left shoulder. Several weeks 
later, a black eschar developed in the center of 
the plaque and enlarged progressively. A similar 
papular lesion of 0.5 mm in diameter appeared 
on the left shoulder. When the patient presented 
for examination, there was a painful reddish 3x1.5 
cm plaque on the right shoulder, at the deltoid 
muscle insertion in the humerus. The plaque was 
indurated and poorly delimited with a central ne-
crotic area. Removal of the black eschar revealed 
a deep ulcer with fibrinous content (Fig. 1). A 
small erythematous papule was present on the left 
shoulder. Cultures for bacterial and fungal agents 
were negative. Skin biopsy taken from the inflam-
matory margin of the ulcerated lesion showed su-
perficial erosion of the epidermis with necrotic ke-
ratinocytes, and dermal necrosis extending to the 
subcutaneous fat. Mononuclear cells, neutrophils 
and eosinophils were present within the superficial 
and deep dermis in perivascular, periadnexal and 
interstitial locations. Focal red blood cell extrava-
sation was also noted, but no signs of vasculitis 
were present. At the moment of our observation, 
laboratory studies including ESR, CRP, liver en-
zymes and complement fraction were within the 
normal range. Cryoglobulins and HCV-RNA level 
were undetectable. The lesion was treated with 
antiseptics and topical corticosteroids and re-
solved slowly over 2 months. The lesion on the left 
shoulder was treated with topical corticosteroids 
with complete resolution in two weeks. PEG-IFN-
α 2b continued to be injected subcutaneously into 
the thigh, without interruption or dose modification 
for another four months. No new cutaneous le-
sions developed either at the injection site or else-
where. 
dISCUSSIon
 The most common side effects of PEG-IFN-α 
are similar to those of IFN-α, including mild, re-
versible bone marrow suppression and flu-like 
symptoms (7). Injection site reactions are con-
sidered as mild to moderate in severity, and most 
consist of local inflammatory reactions. They occur 
at approximately twice the incidence with PEG-
IFN-α treatment compared to IFN-α, possibly due 
to longer serum half-life of PEG-IFN resulting in 
greater tissue permeation. Mild inflammation with-
out serious or persistent reaction has been noted 
in approximately 40%-45% of patients (8), and is 
more common during the first injections (4). In the 
literature there have been case reports of sarcoid-
osis and eczematous reaction patterns of adverse 
dermatologic effects during PEG-IFN-α treatment 
for chronic hepatitis C (9-11). Cutaneous necro-
ses are unusual and occur without age or sex 
predominance, and regardless of whether the IFN 
injection is given subcutaneously or intramuscu-
larly. Although reported to arise most frequently 
on the abdominal wall and the anterior surface 
of the thighs, they can also be seen overlying the 
deltoid or triceps. Necrotic reactions are usually 
delayed, as they most often occur 2-3 months of 
the start of treatment, but can be observed from 
few weeks to years after therapy initiation. They 
are not correlated to the dose or frequency of 
administration. Erythematous and often painful 
patches or indurated nodules become violaceous 
and then necrotic with a minimally purulent base. 
The necrosis spreads progressively and forms a 
dry, black escharotic plaque with irregular borders, 
often angular and well defined. The size of the ul-
ceration varies from several millimeters to 10 cm 
in diameter. The edge of the ulceration is com-
prised of a large inflammatory plaque, infiltrated 
on palpation and poorly delimited. The lesions can 
be multiple. Resolution under treatment is slow, 
taking weeks to months, leaving hyperpigmented 
and atrophic scars (12). Although the exact mech-
anism involved in the pathogenesis of cutaneous 
necrosis remains unknown, several observations 
support different pathogenic mechanisms: hyper-
coagulability, local vasospastic effect, intra-arteri-
olar injection and immune-mediated mechanisms 
(8,12-14). Our observation emphasizes the occur-
rence of cutaneous necrosis following injection of 
the pegylated form of IFN-α (2,6,8,15). Usually the Figure 1. Necrotic ulcer occurred 3 cm below the site of pegylated interferon injections.
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skin lesion develops at the injection site, but in our 
patient the reaction occurred three cm below the 
site of injection, at deltoid muscle insertion in the 
humerus. We postulate a physical concentration 
of IFN in this area. 
 It has been suggested that injections site reac-
tions including skin necrosis are more likely if the 
IFN powder is not reconstituted with the appropri-
ate volume of diluent, resulting in an inappropriate-
ly high concentration of the drug (13). This explains 
the intermittent nature of these reactions in patients 
who prepare the injection by themselves. Rotation of 
injection sites has been recommended to decrease 
the additive inflammatory effects of repeated injec-
tions in the same site (14,15). Medical treatment 
is mostly based on the application of hydrocolloid 
bandages to hasten healing, associated with lo-
cal and systemic antibiotics in the rare cases of 
superinfection. It is sometimes necessary to resort 
to surgical debridement and excision of the lesion, 
followed by direct suturing or grafting. Continuation 
of IFN injection at distant sites is possible for most 
patients, but can be complicated by the appear-
ance of new cutaneous necroses at the new injec-
tion sites, which may necessitate discontinuation of 
the drug. Prevention requires competent training in 
self injection, with as much rotation as possible of 
the injection site, and particular vigilance in cases 
of erythema showing persistence for several days 
at the injection site (14). Because PEG-IFN has al-
most completely replaced IFN for its most frequent 
indications, continuous awareness of the possibility 
of cutaneous necrosis is relevant to early diagnosis 
and to change injection site.
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